114 related articles for article (PubMed ID: 10737525)
1. Re: Estramustine phosphate withdrawal syndrome with dramatic pain relief.
Bissada NK; Kaczmarck AT
J Urol; 2000 Apr; 163(4):1261. PubMed ID: 10737525
[No Abstract] [Full Text] [Related]
2. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
3. Estramustine phosphate withdrawal syndrome with dramatic pain relief.
Shibata Y; Morita T; Kashiwagi B; Tomizawa H; Yamanaka H
J Urol; 1999 Sep; 162(3 Pt 1):805. PubMed ID: 10458378
[No Abstract] [Full Text] [Related]
4. [The place of estramustine in the treatment of prostate cancer].
Pintér O; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Holman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I
Orv Hetil; 2005 Mar; 146(12):553-7. PubMed ID: 15853064
[TBL] [Abstract][Full Text] [Related]
5. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
6. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
Burch PA; Loprinzi CL
J Clin Oncol; 1999 Mar; 17(3):1087-8. PubMed ID: 10071307
[No Abstract] [Full Text] [Related]
8. What next after hormonotherapy in cancer prostate?
Parvez T; Al-sisi H; Ibraheim I
J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
[TBL] [Abstract][Full Text] [Related]
9. Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer.
Pintér O; Molnár J; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Hollman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I; Pajor L
In Vivo; 2005; 19(4):787-92. PubMed ID: 15999550
[TBL] [Abstract][Full Text] [Related]
10. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
Suzuki M; Mamun MR; Hara K; Ozeki T; Yamada Y; Kadowaki T; Honda H; Yanagihara Y; Ito YM; Kameyama S; Ohta N; Hosoi T; Arai T; Sawabe M; Takeuchi T; Takahashi S; Kitamura T
Eur Urol; 2005 Nov; 48(5):752-9. PubMed ID: 16126332
[TBL] [Abstract][Full Text] [Related]
11. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
Duchesne GM; Syme R; Howell D
J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
[No Abstract] [Full Text] [Related]
12. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
13. Biochemical failure: role for early hormonal therapy.
Amling CL
BJU Int; 2004 Dec; 94 Suppl 3():9-10. PubMed ID: 15521886
[No Abstract] [Full Text] [Related]
14. Penile metastasis of prostatic adenocarcinoma.
Senkul T; Karademir K; Silit E; Işeri C; Erden D; Baloğlu H
Int J Urol; 2002 Oct; 9(10):597-8. PubMed ID: 12445240
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
Asahi H; Mizokami A; Maeda Y; Komatsu K; Koshida K; Namiki M
J Urol; 2003 Jan; 169(1):281-2. PubMed ID: 12478161
[No Abstract] [Full Text] [Related]
16. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
17. PSA response to thalidomide in patients with advanced prostate cancer.
Leibowitz R; Tucker SJ
Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944
[No Abstract] [Full Text] [Related]
18. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
Miller K
MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
[No Abstract] [Full Text] [Related]
19. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
Dawson NA; McLeod DG
J Urol; 1995 Jun; 153(6):1946-7. PubMed ID: 7538601
[TBL] [Abstract][Full Text] [Related]
20. [Diferelin treatment of primary local and generalized cancer of the prostate].
Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
Urologiia; 2001; (6):17-9. PubMed ID: 11785073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
